The Norwegian Tenecteplase Stroke Trial 2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 201 participants.

Also called NCT03854500

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03854500
Main results
  • Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial The Lancet. Neurology, 2022-06 DOI, PubMed 35525250

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Norway (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03854500. Randomized; double masking; primary purpose treatment. Start 2019-10-28 (actual); primary completion 2021-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Norwegian Tenecteplase Stroke Trial 2
Acronym
NOR-TEST 2
Condition
Stroke, Acute
Condition
Cerebrovascular Disorders
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Alteplase
Lead sponsor
Haukeland University Hospital (class: other)

Record details

Record id
cardio:ct-nct03854500
Content hash
6d40df9bb6592a57277eaff80aee0690ebe2edfe437fd9a4d43de37df8d75d4b